Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Freya Meds vs Willow

Freya Meds
Graded #364

Higher grade

vs+0.3999999999999986
Willow
Graded #377

Lower grade

The verdict

Freya Meds takes it — 58.6/100 to 58.2/100, but only just.

Freya Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Freya Meds is a GLP-1 specialist offering compounded semaglutide ($250–$297/mo) and compounded tirzepatide ($332–$390/mo). Willow is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFreya Meds +7
43
36
Dose & formulationWillow +11
64
75
Clinical oversightEven
71
71
Labs & monitoringFreya Meds +8
60
52
FulfillmentWillow +3
62
65
Contract termsEven
55
55
Freya Meds · left barWillow · right bar

The numbers

MetricFreya MedsWillow
WeighScore58.6/10058.2/100
GradeCC
Scorecard rank#364#377
Semaglutide$297/mo (compounded)$299/mo (starting dose, compounded)
Tirzepatide$390/mo (compounded)$399/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Freya Meds

Graded #364 · C

Strengths

  • GLP-1 specialist — not a multi-category telehealth
  • Price includes unlimited doctor consultations, monthly group calls, and a dietitian consultation
  • Both semaglutide and tirzepatide available
  • Multi-month discount on quarterly billing
  • Claims 450,000+ enrolled

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • Above-average pricing ($250–$390/mo)
  • Compounded only — no brand-name options
  • Now serves 49 U.S. states (one state excluded; specific exclusion not named)
Willow

Graded #377 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard